%0 Journal Article
%T Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.
%A Muñoz-Casares FC
%A Martín-Broto J
%A Cascales-Campos P
%A Torres-Melero J
%A López-Rojo I
%A Gómez-Barbadillo J
%A González-Bayón L
%A Sebio A
%A Serrano C
%A Carvalhal S
%A Abreu de Souza J
%A Souza A
%A Flores-Ayala G
%A Palacios Fuenmayor LJ
%A Lopes-Bras R
%A González-López JA
%A Vasques H
%A Asencio-Pascual JM
%J Cancers (Basel)
%V 16
%N 15
%D 2024 Jul 25
%M 39123374
%F 6.575
%R 10.3390/cancers16152646
%X Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts' voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas.